Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus

Vaccine

Volumn 12, Issue 10, 1994, Pages 933-939

  Ukae, Susumu ^a   Nakata, Shuji ^a   Adachi, Noriaki ^a   Kogawa, Keiko ^a   Chiba, Shunzo ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

heterotypic immunity; neutralizing serum antibody; Rhesus rotavirus vaccine; serotype 1 rotavirus gastroenteritis; serotype specific protection

Indexed keywords

IMMUNOGLOBULIN A; ROTAVIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROENTERITIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROTYPE; VACCINATION; VIRUS TRANSMISSION;

ANTIBODIES, VIRAL; CHILD, PRESCHOOL; GASTROENTERITIS; HUMANS; IMMUNOGLOBULIN A; INFANT; INFANT, NEWBORN; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEROTYPING; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0028131477     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(94)90037-X     Document Type: Article

References (32)

1. Rotaviruses
2. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies
3. Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance
4. Prevention of human rotavirus-induced diarrhea in gnotobiotic piglets using bovine antibody
5. Maternal antibody-mediated protection against gastroenteritis due to rotavirus in newborn mice is dependent on both serotype and titer of antibody
6. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants
7. Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies
8. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from immunized cows
9. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen
10. Towards rotavirus vaccines
11. Clinical studies of quadrivalent rotavirus vaccine in Venezuelan infants
12. Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates
13. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine
14. Transmissibility, immunogenicity and booster effect of rhesus rotavirus vaccine MMU-18006
15. Virological and serological aspects of immune resistance to rotavirus gastroenteritis
16. Simultaneous administration of rotavirus vaccine MMU-18006 and poliovirus vaccine
17. Antigenic characterization and ELISA detection of adult diarrhea rotaviruses
18. Direct serotyping of human rotavirus in stools by an enzyme-linked immunosorbent assay using serotypes 1-, 2-, 3-, and 4-specific monoclonal antibodies to VP7
19. Simultaneous administration of two human-rhesus rotavirus reassortant strains of VP7 serotype 1 and 2 specificity to infants and young children
20. Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity
21. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants
22. Sequential administration of two human-rhesus rotavirus reassortant strains of VP7 serotype 1 and 2 specificity to infants and young children
23. Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody
24. Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in sucking mice
25. Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes
26. Antibody response to serotype-specific and cross-reactive neutralization epitopes on VP4 and VP7 after rotavirus infection or vaccination
27. Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers
28. Characterization of serum antibody responses to natural rotavirus infections in children by VP7-specific epitope-blocking assays
29. Intestinal and serum immune response to a naturally acquired rotavirus gastroenteritis in children
30. Effect of antibody to rotavirus on protection of adults challenged with a human rotavirus
31. Role of coproantibody in clinical protection of children during reinfection with rotavirus
32. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections